Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Victhom Human Bionics Inc V.VHB



TSXV:VHB - Post by User

Bullboard Posts
Post by gldblvon Jan 07, 2009 9:28pm
250 Views
Post# 15690052

That should create some volume

That should create some volume
QUEBEC, Jan. 7 /CNW Telbec/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA on January 13 and 14, 2009. Nader Kameli, Chief Operating Officer of Victhom's Neurobionix division, will be presenting on Tuesday, January 13 at 9:00 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell Street. Information about the OneMedPlace Finance Forum may be found at https://www.onemedplace.com.

Victhom has developed the Neurostep(R) System, an implantable neurostimulation device designed to restore mobility and independence for patients with partial paralysis of the leg as a result of hemiparetic stroke. The Neurostep(R) System has been engineered to integrate with the body's natural sensing and stimulation network and designed to closely mimic specific functions that have been interrupted or lost due to disease or injury. The Neurostep(R) is an investigational medical device currently in human clinical study in four clinical sites outside U.S. and is planned for market introduction in Europe late 2009.

Bullboard Posts